ClinicalTrials.gg
Not yet recruitingNCT07941258DEX-POD-GIUpdated Nov 17, 2026

Dexmedetomidine for Preventing Postoperative Delirium and a Risk Prediction Nomogram in Older Adults Undergoing Gastrointestinal Surgery

An interventional study of Dexmedetomidine and Placebo in Postoperative Delirium, Gastrointestinal Surgery and Aged, sponsored by Hanoi Medical University. Not yet recruiting at 1 site in Vietnam. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Hanoi Medical University · Not applicable, Interventional, and Prevention

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
630
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 83 studies testing dexmedetomidine in Emergence Delirium — 31 open to participants now, 32 under way, 2 of them phase 3. Dexmedetomidine · Emergence Delirium.

Planned enrollment
3rd of 83
630 · median 100
Started
2026
with 15 others
No phase
27 of 83
13 open now
Primary completion
2028-04
later than 30 of 31 live
Registered
83rd of 83
by date

Among the 83 studies testing dexmedetomidine in Emergence Delirium, this one is the 3rd largest by planned enrollment, is one of 16 that started in 2026, is one of 27 with no phase, reaches primary completion later than 30 of the 31 other live ones, and was the 83rd registered.

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

Browse Emergence Delirium studies →

Open to participants now

31 of the 83 studies testing dexmedetomidine in Emergence Delirium are open now, in 10 countries. Recruiting first, the newest first:

25 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing dexmedetomidine in Emergence Delirium, or all of them as a file.
02

Study summary

Postoperative delirium (POD) is a common and serious complication in older adults after major gastrointestinal surgery and is associated with longer hospital stay, long-term cognitive decline and higher mortality. Dexmedetomidine, a highly selective alpha-2 adrenergic agonist with sedative, anti-inflammatory and opioid-sparing effects, may reduce POD, but evidence in older patients undergoing gastrointestinal surgery remains inconsistent, and tools to identify which patients are at highest risk are lacking.

The goal of this randomized, double-blind, placebo-controlled trial is to learn whether intraoperative and early postoperative dexmedetomidine prevents POD in patients aged 60 years or older undergoing elective gastrointestinal surgery under general anesthesia, and to develop a risk prediction nomogram for POD in this population. The main questions it aims to answer are:

  1. Does dexmedetomidine lower the incidence of POD within 5 days after surgery compared with placebo, and is it safe?
  2. How accurately can a prediction model (nomogram) built from preoperative and intraoperative factors estimate each patient's risk of POD?

Researchers will also examine how dexmedetomidine changes postoperative inflammatory and stress markers (IL-6, cortisol, CRP, NLR, SII) and their association with POD, and whether the benefit of dexmedetomidine differs across baseline-risk strata.

Participants will be randomly assigned to dexmedetomidine or placebo (0.9% saline). The blinded infusion starts 15 minutes before induction of anesthesia (dexmedetomidine 0.5 mcg/kg over 15 minutes, then 0.5 mcg/kg/h until 2 hours after surgery, or the same volume and rate of saline). Delirium will be assessed three times daily with the 3D-CAM (or CAM-ICU for patients who cannot be interviewed) from the end of surgery until postoperative day 5 or hospital discharge.

Read the detailed description

Design: Single-center, randomized, double-blind, placebo-controlled, parallel-group (1:1) superiority trial with an embedded prediction-model development study, conducted at Hanoi Medical University Hospital, Hanoi, Vietnam. The protocol follows SPIRIT 2025; results will be reported according to CONSORT 2025 and prediction models according to TRIPOD+AI 2024. Approved by the Hanoi Medical University Institutional Ethical Review Board (certificate 5315/GCN-DHYHN, HMUIRB3022, 2 November 2026).

Primary outcomes: (1) Incidence of POD through postoperative day 5 - tested two-sided at alpha 0.05. (2) Predictive performance of the POD nomograms (optimism-corrected C-statistic, calibration slope and intercept, Brier score) - reported as point estimates with 95% CI, without hypothesis testing; therefore no alpha splitting is applied. All other analyses are secondary and interpreted as exploratory.

Randomization and allocation concealment: An independent investigator not involved in recruitment or assessment generates the allocation sequence in R using permuted blocks of randomly varying size. Sequentially numbered, opaque, sealed envelopes (1-630) are opened in the operating room by an independent nurse who prepares the study drug.

Blinding: Participants, anesthesiologists, surgeons, ward nurses, delirium assessors, laboratory staff and data analysts are blinded. Dexmedetomidine (200 mcg in 50 mL, 4 mcg/mL) and placebo (50 mL 0.9% saline) are prepared in identical 50-mL syringes with identical labels, volume and infusion rate. Emergency unblinding is permitted only when knowledge of allocation would change clinical management.

Anesthesia protocol: No benzodiazepine premedication; anticholinergics minimized. Induction with fentanyl 2 mcg/kg, titrated propofol to PSi 25-50, rocuronium 0.8 mg/kg; maintenance with sevoflurane titrated to PSi 25-50; TOF-guided neuromuscular blockade; protective ventilation; non-invasive blood pressure every 3 minutes. Postoperative analgesia per routine practice, with regional techniques according to surgery; total opioid use is recorded.

Delirium assessment: Trained, blinded assessors (inter-rater kappa >= 0.8) perform the 3D-CAM three times daily (07:00-09:00, 12:00-14:00, 18:00-20:00) from the end of surgery through postoperative day 5 or hospital discharge. Sedation is assessed with RASS before each assessment; patients with RASS -3 to -1 who cannot be interviewed are assessed with CAM-ICU. Severity is graded by 3D-CAM-S. 10% of assessments are double-rated for quality control.

Laboratory substudy: The first 60 randomized patients (30 per group) undergo IL-6 (baseline, 2 h and 24 h after surgery) and 08:00 cortisol (baseline, postoperative days 1 and 2) measurements. CRP and complete blood count (for NLR and SII) are measured in all patients before surgery and at 24 h and 48 h after surgery. The substudy is analyzed after the 60 patients complete follow-up; this pre-specified secondary analysis excludes delirium outcomes and is not used for any decision on stopping, sample size or protocol modification.

Sample size: Primary outcome 1: assuming POD incidence of 25% with placebo and 10% with dexmedetomidine (Lee et al., 2018), alpha 0.05 and power 80%, 224 patients (112 per group, including 10% attrition) are required. Primary outcome 2: following Riley et al. (2020) (outcome prevalence 17.5%, up to 6 candidate parameters, Cox-Snell R-squared 0.0907), at least 566 patients are required; allowing 10% attrition, 630 patients (315 per group) will be enrolled. The sample size is therefore driven by primary outcome 2 and gives more than 80% power for primary outcome 1.

Statistical analysis: The primary analysis population is the modified intention-to-treat (mITT) population (all randomized patients who started study-drug infusion), with per-protocol sensitivity analysis; safety is analyzed by treatment received. Primary outcome 1 is compared with chi-square/Fisher's exact test and reported as RR, absolute risk difference and NNT with 95% CI; adjusted RR by robust Poisson regression (age, MMSE, high-risk surgery and covariates with \|SMD\| > 0.1). Biomarker trajectories are analyzed with linear mixed-effects models. Missing data are handled by multiple imputation (MICE, 20 datasets) with complete-case and best/worst-case sensitivity analyses. Pre-specified subgroups: age \< 75 vs >= 75, high-risk surgery, open vs laparoscopic, MMSE \< 24 vs >= 24, CFS \<= 4 vs >= 5. No interim efficacy analysis is planned.

Prediction models: Pre-specified logistic models (no data-driven variable selection, maximum 6 parameters, uniform bootstrap shrinkage): Model A (preoperative: age, MMSE, Clinical Frailty Scale, serum albumin, high-risk surgery, treatment group) and Model B (end of surgery: age, MMSE, CFS, surgical duration, cumulative time with MAP \< 65 mmHg, treatment group; plus a sensitivity version updating the Model A linear predictor). Internal validation by 1,000 bootstrap replicates; temporal validation when >= 30 events are available. Secondary: model comparison, decision curve analysis over thresholds of 5-40%, and treatment-effect heterogeneity by quartiles of baseline risk from Model A following the PATH statement (pre-specified, exploratory). Nomograms are research products and will not guide treatment of trial participants.

Safety monitoring: An independent monitoring group reviews safety after 25%, 50% and 75% of enrollment or every 6 months, whichever comes first. Serious adverse events are reported to the ethics committee within 24 hours.

03

Conditions studied

  • Postoperative Delirium
  • Gastrointestinal Surgery
  • Aged

Browse trials for

Keywords

  • dexmedetomidine
  • postoperative delirium
  • older adults
  • gastrointestinal surgery
  • nomogram
  • prediction model
  • 3D-CAM
  • interleukin-6
  • cortisol
  • neutrophil-to-lymphocyte ratio
  • systemic immune-inflammation index
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 60 years or older
  • Scheduled for elective gastrointestinal surgery (esophageal, gastroduodenal, small bowel, colorectal, hepatobiliary, pancreatic or splenic) under general anesthesia
  • (ASA) physical status I-III
  • Written from the patient, or from a legally authorized representative if the patient lacks decision-making capacity

Exclusion criteria

Exclusion Criteria:

  • Expected duration of surgery \< 90 minutes
  • Preoperative delirium
  • Severe preoperative cognitive impairment ( score \< 14)
  • Communication difficulties preventing completion of study assessments
  • to dexmedetomidine: known allergy, bradycardia, second- or third-degree atrioventricular block without a pacemaker, or current high-dose beta-blocker therapy
  • Hepatic failure ( class B or C) or end-stage renal disease requiring dialysis
  • Substance dependence or abuse, or current use of antipsychotic medication
  • Cancer with brain or bone causing severe preoperative pain
  • Refusal by the patient or family to participate

Withdrawal criteria (after randomization): severe anesthetic or surgical complications (e.g., anaphylaxis, local anesthetic systemic toxicity, hemorrhagic shock); premature discontinuation of study drug due to adverse effects; actual surgical duration \< 90 minutes; postoperative mechanical ventilation > 24 hours; re-anesthesia, spinal anesthesia or reoperation during the study period; withdrawal of consent. Patients withdrawn after starting the infusion remain in the mITT analysis.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
630 participants (estimated)

Study arms

  • Experimental
    Dexmedetomidine

    Dexmedetomidine 4 mcg/mL (200 mcg in 50 mL 0.9% saline). Loading dose 0.5 mcg/kg infused over 15 minutes starting 15 minutes before induction of general anesthesia, followed by a maintenance infusion of 0.5 mcg/kg/h throughout surgery until 2 hours after the end of surgery.

    Drug: Dexmedetomidine

  • Placebo comparator
    Placebo (0.9% saline)

    0.9% sodium chloride 50 mL in an identical syringe, infused at the same volume, rate and duration as the dexmedetomidine arm (15-minute loading infusion before induction, then maintenance until 2 hours after the end of surgery).

    Drug: Placebo

Interventions

  • Selective alpha-2 adrenergic agonist. Dexmedetomidine Invagen 200 mcg/2 mL (SIA Pharmidea, Latvia; Vietnamese marketing authorization 475114010723). Dose reduced to 0.3 mcg/kg/h for bradycardia with hypotension; stopped for HR \< 40/min, new 2nd-3rd degree AV block, refractory hypotension, or RASS \<= -3 / SpO2 \< 90% after extubation.

    Also known as: Dexmedetomidine hydrochloride, Dexmedetomidine Invagen

  • DrugPlacebo

    Identical-appearing 0.9% sodium chloride solution administered with the same syringe, label, volume, rate and duration.

    Also known as: 0.9% sodium chloride, normal saline

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative delirium

    Percentage of participants with at least one positive delirium assessment. Delirium is assessed with the 3-Minute Diagnostic Interview for Confusion Assessment Method-defined delirium (3D-CAM), or with the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) in patients who cannot be interviewed (Richmond Agitation-Sedation Scale \[RASS\] score -3 to -1; RASS range -5 \[unarousable\] to +4 \[combative\]). Both instruments give a dichotomous result (delirium present/absent). Assessments are performed three times daily (07:00-09:00, 12:00-14:00, 18:00-20:00) by blinded trained assessors.

    Time frame: From the end of surgery through postoperative day 5 or hospital discharge, whichever comes first

  2. Discrimination of the postoperative delirium nomograms (C-statistic)

    Optimism-corrected C-statistic (area under the ROC curve; unitless, range 0.5-1.0, higher = better discrimination) of Model A (preoperative nomogram: age, MMSE, Clinical Frailty Scale, serum albumin, high-risk surgery, treatment group) and Model B (end-of-surgery nomogram: age, MMSE, Clinical Frailty Scale, surgical duration, cumulative time with MAP \< 65 mmHg, treatment group), internally validated with 1,000 bootstrap replicates. Reported separately for each model.

    Time frame: From the end of surgery through postoperative day 5

  3. Calibration slope of the postoperative delirium nomograms

    Optimism-corrected calibration slope (unitless; ideal value 1; values below 1 indicate overfitting) of Model A and Model B, estimated by 1,000 bootstrap replicates. Reported separately for each model.

    Time frame: From the end of surgery through postoperative day 5

  4. Calibration-in-the-large of the postoperative delirium nomograms

    Optimism-corrected calibration intercept (calibration-in-the-large; log-odds scale; ideal value 0) of Model A and Model B, estimated by 1,000 bootstrap replicates. Reported separately for each model.

    Time frame: From the end of surgery through postoperative day 5

  5. Brier score of the postoperative delirium nomograms

    Optimism-corrected Brier score (mean squared difference between predicted probability and observed outcome; range 0-1, lower = better overall accuracy) of Model A and Model B, estimated by 1,000 bootstrap replicates. Reported separately for each model.

    Time frame: From the end of surgery through postoperative day 5

Secondary outcomes

  1. Severity of postoperative delirium

    Highest score on the 3D-CAM Severity scale (3D-CAM-S; range 0-7, higher scores mean more severe delirium; 0 none, 1 mild, 2 moderate, 3-7 severe) among all assessments.

    Time frame: From the end of surgery through postoperative day 5

  2. Time to onset of postoperative delirium

    Hours from the end of surgery to the first positive delirium assessment; participants without delirium are censored at the last assessment.

    Time frame: From the end of surgery through postoperative day 5

  3. Duration of postoperative delirium

    Days from the first positive delirium assessment until delirium is no longer diagnosed.

    Time frame: From the end of surgery through postoperative day 5

  4. Motor subtype of postoperative delirium

    Number of participants with each motor subtype among those with delirium: hyperactive (RASS always \> 0), hypoactive (RASS always \<= 0) or mixed, based on RASS (range -5 to +4) at positive assessments.

    Time frame: From the end of surgery through postoperative day 5

  5. Incidence of bradycardia requiring treatment

    Percentage of participants with heart rate \< 50 beats/min or a decrease \>= 20% from baseline requiring treatment.

    Time frame: From the start of study-drug infusion to 2 hours after the end of surgery

  6. Incidence of hypotension requiring treatment

    Percentage of participants with mean arterial pressure \< 65 mmHg or a decrease \>= 20% from baseline requiring fluid or vasopressor.

    Time frame: From the start of study-drug infusion to 2 hours after the end of surgery

  7. Cumulative intraoperative hypotension time

    Total minutes with mean arterial pressure \< 65 mmHg (non-invasive blood pressure measured every 3 minutes).

    Time frame: From induction of anesthesia to the end of surgery

  8. Study-drug dose reduction or discontinuation

    Percentage of participants whose study-drug infusion was reduced or stopped because of adverse effects.

    Time frame: From the start of study-drug infusion to 2 hours after the end of surgery

  9. Time to extubation

    Minutes from the end of surgery to tracheal extubation.

    Time frame: Up to 24 hours after surgery

  10. Length of stay in the post-anesthesia care unit

    Minutes from admission to discharge from the post-anesthesia care unit.

    Time frame: Up to 24 hours after surgery

  11. Postoperative pain intensity

    Pain score on the Visual Analog Scale (VAS; range 0-10 cm, 0 = no pain, 10 = worst imaginable pain; higher scores mean worse pain).

    Time frame: 12, 24 and 48 hours after surgery

  12. Postoperative opioid consumption

    Cumulative opioid dose converted to intravenous morphine milligram equivalents.

    Time frame: From induction of anesthesia to 48 hours after surgery

  13. Major postoperative complications

    Percentage of participants with complications of Clavien-Dindo grade III or higher (Clavien-Dindo classification, grades I-V; higher grades mean more severe complications).

    Time frame: Until hospital discharge (up to 30 days after surgery)

  14. Postoperative length of hospital stay

    Days from surgery to hospital discharge.

    Time frame: Until hospital discharge (up to 30 days after surgery)

  15. In-hospital mortality

    Percentage of participants who die from any cause during hospitalization.

    Time frame: Until hospital discharge (up to 30 days after surgery)

  16. Plasma interleukin-6 (IL-6) concentration

    IL-6 concentration (pg/mL) in the laboratory substudy (first 60 participants, 30 per group).

    Time frame: Before surgery (baseline), 2 hours and 24 hours after the end of surgery

  17. Serum cortisol concentration

    08:00 serum cortisol concentration (nmol/L) in the laboratory substudy (first 60 participants).

    Time frame: 08:00 on the day of surgery before induction (baseline), 08:00 on postoperative day 1 and 08:00 on postoperative day 2

  18. Serum C-reactive protein (CRP) concentration

    CRP concentration (mg/L) in all participants.

    Time frame: Before surgery (baseline), 24 hours and 48 hours after the end of surgery

  19. Neutrophil-to-lymphocyte ratio (NLR)

    Absolute neutrophil count divided by absolute lymphocyte count (unitless ratio) from complete blood count, in all participants.

    Time frame: Before surgery (baseline), 24 hours and 48 hours after the end of surgery

  20. Systemic immune-inflammation index (SII)

    Platelet count x neutrophil count / lymphocyte count (x10\^9/L) from complete blood count, in all participants.

    Time frame: Before surgery (baseline), 24 hours and 48 hours after the end of surgery

  21. Area under the ROC curve of laboratory markers for postoperative delirium

    Area under the receiver operating characteristic curve (AUC; unitless, range 0.5-1.0, higher = better discrimination, with DeLong 95% CI) of each marker (IL-6, cortisol, CRP, NLR, SII) for identifying postoperative delirium. Reported separately for each marker.

    Time frame: Markers measured from baseline to 48 hours after surgery; delirium assessed from the end of surgery through postoperative day 5

  22. Adjusted odds ratio of postoperative delirium associated with CRP, NLR and SII

    Odds ratio (with 95% CI) for postoperative delirium per unit increase in each postoperative marker (CRP, NLR, SII), from multivariable logistic regression adjusted for age, MMSE, treatment group and high-risk surgery. Reported separately for each marker.

    Time frame: Markers measured at 24 and 48 hours after surgery; delirium assessed from the end of surgery through postoperative day 5

  23. Clinical net benefit of the postoperative delirium nomograms

    Net benefit (unitless) by decision curve analysis across threshold probabilities of 5-40%, compared with treat-all and treat-none strategies, for Model A and Model B.

    Time frame: From the end of surgery through postoperative day 5

  24. Absolute risk difference in postoperative delirium by baseline-risk stratum

    Difference in the percentage of participants with postoperative delirium (dexmedetomidine minus placebo, percentage points, with 95% CI) within each quartile of baseline delirium risk estimated by Model A (treatment set to placebo). The number needed to treat is derived as 1/absolute risk difference. Pre-specified exploratory analysis.

    Time frame: From the end of surgery through postoperative day 5

  25. Relative risk of postoperative delirium by baseline-risk stratum

    Ratio of the risk of postoperative delirium (dexmedetomidine vs placebo, with 95% CI) within each quartile of baseline delirium risk estimated by Model A; heterogeneity explored by a baseline risk x treatment interaction term. Pre-specified exploratory analysis.

    Time frame: From the end of surgery through postoperative day 5

07

Study locations

1 site
08

References and documents

Publications

  • Xu W, Zheng Y, Suo Z, Fei K, Wang Y, Liu C, Li S, Zhang M, Zhang Y, Zheng Z, Ni C, Zheng H. Effect of dexmedetomidine on postoperative systemic inflammation and recovery in patients undergoing digest tract cancer surgery: A meta-analysis of randomized controlled trials. Front Oncol. 2022 Sep 14;12:970557. doi: 10.3389/fonc.2022.970557. eCollection 2022. PubMed 36185178 ↗
  • Riley RD, Ensor J, Snell KIE, Harrell FE Jr, Martin GP, Reitsma JB, Moons KGM, Collins G, van Smeden M. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020 Mar 18;368:m441. doi: 10.1136/bmj.m441. No abstract available. PubMed 32188600 ↗
  • Lee C, Lee CH, Lee G, Lee M, Hwang J. The effect of the timing and dose of dexmedetomidine on postoperative delirium in elderly patients after laparoscopic major non-cardiac surgery: A double blind randomized controlled study. J Clin Anesth. 2018 Jun;47:27-32. doi: 10.1016/j.jclinane.2018.03.007. Epub 2018 Mar 14. PubMed 29549829 ↗

Individual participant data

Plan to share: Undecided — De-identified individual participant data underlying the published results, together with the statistical analysis code, may be shared upon reasonable request to the principal investigator after publication of the main results. A final decision will be made before study completion.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2028, 16 months later.

Of 186 non-industry interventional studies with no phase under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 16 months is below that.

Counting every sponsor, half of 186 studies reached it within 19 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Apr 30, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941258
Lead sponsor
Hanoi Medical University
Responsible party
Le Van Tien (MD, Anesthesiologist, PhD Candidate, Hanoi Medical University) — Principal investigator
First posted
Nov 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Apr 30, 2028 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Tien Le Van, MD
Contact
levantien.yhn@gmail.com
+84348869686
Tien Le Van, MD
principal investigator · Hanoi Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion